Near-infrared activatable phthalocyanine-poly-L-glutamic acid conjugate: increased cellular uptake and light-dark toxicity ratio toward an effective photodynamic cancer therapy
Autores de CIPF
Participantes ajenos a CIPF
- Kiew, LV
- Cheah, HY
- Voon, SH
- Ng, KH
- Alpugan, S
- Lee, HB
- Dumoulin, F
- Chung, LY
Grupos de Investigación
Abstract
In photodynamic therapy (PDT), the low absorptivity of photosensitizers in an aqueous environment reduces singlet oxygen generation efficiency and thereby decreases photosensitizing efficacy in biological conditions. To circumvent this problem, we designed a phthalocyanine-poly-L-glutamic acid conjugate (1-PG) made from a new phthalocyanine (Pc 1) monofunctionalized to allow adequate conjugation to PGA. The resulting 1-PG conjugate retained high absorptivity in the near-infrared (NIR) region at its.max 675 nm in an aqueous environment. The 1-PG conjugate demonstrated good singlet oxygen generation efficiency, increased uptake by 4 T1 breast cancer cells via clathrin-mediated endocytosis, and enhanced photocytotoxic efficacy. The conjugate also displayed a high light-dark toxicity ratio, approximately 1.5-fold greater than zinc phthalocyanine at higher concentration (10 mu M), an important feature for the reduction of dark toxicity and unwanted side effects. These results suggest that the 1-PG conjugate could be a useful alternative for deep tissue treatment with enhanced anti-cancer (PDT) efficacy. (C) 2017 Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1549-9634, 1549-9642
- Tipo:
- Article
- Páginas:
- 1447-1458
- PubMed:
- 28214608
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 30
Documentos
- No hay documentos
Filiaciones
Keywords
- Near-infrared; Poly-L-glutamic acid; Phthalocyanine; Photodynamic therapy; Photosensitizer; Nano-structure
Proyectos asociados
Towards the design of Personalised Polymer-based Combiantion Nanomedicines for Advanced Stage Breast Cancer Patients
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2015
Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica para el tratamiento de desordenes neurodegenerativos-Explorando la Ruta Intranasal.
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE ECON. Y COMPET. . 2016
Desarrollo de un estrategia para la prevención miocárdica del daño inducido por reperfusión basada en el uso de catéteres y polímeros teraéuticos de nueva generación Premicat
Investigador Principal: MARIA JESUS VICENT DOCON
INSTITUTO DE SALUD CARLOS III . 2016